$3.65 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Stock Analysis

last close $3.12
1-mo return -20.2%
3-mo return -8.2%
avg daily vol. 101.18T
52-week high 13.69
52-week low 2.32
market cap. $108M
forward pe -
annual div. -
roe -38.6%
ltg forecast 32.4%
dividend yield -
annual rev. $--
inst own. -

Subscribe now for daily local and international financial news